Apply to trial NCT05450965

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-expressed in many cancer cells and is involved in cellular repair.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening